# Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies

> **NCT07345780** · NA · NOT_YET_RECRUITING · sponsor: **Donghua Zhang** · enrollment: 28 (estimated)

## Conditions studied

- CD7-Positive Hematological Malignancies

## Interventions

- **DRUG:** CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies

## Key facts

- **NCT ID:** NCT07345780
- **Lead sponsor:** Donghua Zhang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07345780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07345780, "Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07345780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*